Hos kvinder med en prævalent rygsøjlefraktur ved baseline reducerede Fablyn signifikant forekomsten af nye radiografisk verificerede rygsøjlefrakturer fra 14, 2% for placebo til 8, 7% for Fablyn (relativ reduktion af risiko = 42%, p = 0, 0004).
In women with a prevalent vertebral fracture at baseline, FABLYN significantly reduced the incidence of new vertebral radiographic fractures from 14.2% for placebo to 8.7% for FABLYN (relative risk reduction = 42%, p = 0.0004).